Business Description
Axsome Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US05464T1043
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.07 | |||||
Equity-to-Asset | 0.33 | |||||
Debt-to-Equity | 0.98 | |||||
Debt-to-EBITDA | -0.83 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 3.2 | |||||
Beneish M-Score | 0.6 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -22.5 | |||||
3-Year EPS without NRI Growth Rate | -17.3 | |||||
3-Year FCF Growth Rate | -15 | |||||
3-Year Book Growth Rate | 9.8 | |||||
Future 3-5Y Total Revenue Growth Rate | 60.03 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 70.1 | |||||
9-Day RSI | 58.45 | |||||
14-Day RSI | 52.3 | |||||
6-1 Month Momentum % | 30.5 | |||||
12-1 Month Momentum % | 14.83 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.63 | |||||
Quick Ratio | 3.52 | |||||
Cash Ratio | 2.78 | |||||
Days Inventory | 130.6 | |||||
Days Sales Outstanding | 87.17 | |||||
Days Payable | 524.04 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.2 | |||||
Shareholder Yield % | -10.04 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 90.37 | |||||
Operating Margin % | -67.59 | |||||
Net Margin % | -88.41 | |||||
FCF Margin % | -53.78 | |||||
ROE % | -124.52 | |||||
ROA % | -47.44 | |||||
ROIC % | -172.3 | |||||
ROC (Joel Greenblatt) % | -4500.41 | |||||
ROCE % | -59.27 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 12.33 | |||||
PB Ratio | 18.28 | |||||
Price-to-Tangible-Book | 27.79 | |||||
EV-to-EBIT | -14.24 | |||||
EV-to-Forward-EBIT | -18.79 | |||||
EV-to-EBITDA | -14.69 | |||||
EV-to-Forward-EBITDA | -19.52 | |||||
EV-to-Revenue | 12.2 | |||||
EV-to-Forward-Revenue | 8.35 | |||||
EV-to-FCF | -22.66 | |||||
Price-to-Net-Current-Asset-Value | 32.6 | |||||
Earnings Yield (Greenblatt) % | -7.02 | |||||
FCF Yield % | -4.16 |